Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ: MDGL) announced that its management team will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 9:30 AM ET. The event will be webcasted, with an archived recording available on the company's website. Madrigal focuses on novel therapeutics for nonalcoholic steatohepatitis (NASH), with its leading candidate, resmetirom, currently undergoing four Phase 3 clinical studies aimed at addressing this significant liver disease.

CONSHOHOCKEN, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in a fireside chat at the H.C. Wainwright 24^th Annual Global Investment Conference on Monday, September 12, 2022 at 9:30 am ET.

The fireside chat will be webcast and an archived recording will be available for replay in the Investors & Media section of the Madrigal website following the event.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in four Phase 3 clinical studies (MAESTRO-NASH, MAESTRO-NAFLD-1, MAESTRO-NAFLD-OLE and MAESTRO-NASH Outcomes) designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.

Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

FAQ

What is the date of the fireside chat for Madrigal Pharmaceuticals (MDGL)?

The fireside chat for Madrigal Pharmaceuticals is scheduled for September 12, 2022.

Where can I watch the fireside chat for MDGL?

The fireside chat for Madrigal Pharmaceuticals will be available as a webcast and can be accessed on their website.

What is the focus of Madrigal Pharmaceuticals (MDGL)?

Madrigal Pharmaceuticals focuses on developing therapies for nonalcoholic steatohepatitis (NASH).

What is Madrigal's lead candidate for treating NASH?

Madrigal's lead candidate for treating NASH is resmetirom, a thyroid hormone receptor selective agonist.

How many clinical studies is resmetirom currently in?

Resmetirom is currently being evaluated in four Phase 3 clinical studies.